Patent · US Active

Combinations and uses thereof

US12194095B2 · kind B2 · utility

0Cited by

16References

28Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

Jan Endell · Munich, DE
Mark Winderlich · Munich, DE
Rainer Boxhammer · Aying, DE

Key dates

Filing date	Dec 8, 2021
Grant date	Jan 14, 2025
Priority date	—
Expiry date	Apr 21, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.